Corcept Therapeutics vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Corcept Therapeutics Incorporated (CORT)

Q3 202627 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

August 202627 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Latest27 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.